Home › Bleeding › NCT07083583

Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders

Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders: a Single-arm Prospective Observational Study

Who can join

Ages 15 and older · All sexes

Inclusion Criteria:

1. Males and Females \> 15 years of age
2. Diagnosed with an Inherited Bleeding Disorder (Von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause)
3. Evidence of Iron Deficiency (Ferritin \< 50 ng/mL)
4. Receiving IV iron at Hemophilia Center of Western Pennsylvania
5. Willingness to have blood drawn
6. Willing to return to clinic 3 months post infusion for final blood draw, bleeding and quality of life assessments.

Exclusion Criteria:

1. Previous thrombosis, VTE History.
2. Platelet count \< 100,000 \* 109/L
3. Concomitant use of antiplatelet drugs, anticoagulants, aspirin, NSAIDs.

About the study

This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin \<50ng/dL). Subjects will undergo baseline bleeding assessments, quality-of-life measures, and laboratory tests before receiving standard-of-care IV iron. Follow-up blood work and questionnaires will be conducted post-replacement to assess for changes

What is being tested

• IV Iron (standard of care) (drug)

Sponsor: Nicoletta C Machin · Participants: 40 · Started: Aug 8, 2025

Contact the study team

• Nicoletta Machin, DO · Phone: (412) 209-7280

Official record on ClinicalTrials.gov — NCT07083583

Locations in the U.S.

Conditions

• Bleeding
• Iron Deficiencies

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.